For lymphoma patients who were mobilized with G-CSF and chemotherapy and apheresed to a goal of ≥2 × 106 CD34+ cells/kg, there was also no statistically significant difference in requirement of >1 day of apheresis between patients given Neupogen® and Grastofil® (42.1% vs. 36.8%, respectively, p = 0.67). This evidence concerns the gene CSF3 and lymphoma.